Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/16/2023 | $20.00 | Neutral → Buy | BofA Securities |
| 7/19/2022 | $21.00 → $24.00 | Market Perform → Outperform | Cowen |
| 10/7/2021 | Overweight → Equal-Weight | Morgan Stanley |
- Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma - ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care Regimen in Europe - Second Approval in Frontline Hodgkin Lymphoma Broadens ADCETRIS' Therapeutic Reach, Adding to Six Previously Approved, Distinct Indications for ADCETRIS in the European Union Takeda ((TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with ne
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig
− Award supports emerging biomedical researchers globally focused on gastrointestinal and inflammatory diseases, neuroscience and oncology Takeda ((TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking research with a focus on emerging scientific leaders who are advancing the frontiers of scientific discovery and fostering innovation that has the potential to transform lives. In 2026, the Takeda Innovators in Science Award with Nature will recognize promising early-career scientists in the areas of gastrointestinal and inflammatory diseases, neuroscience, and oncology.